Business Standard Ozempic patent expiry set to trigger weight-loss drug boom in India
India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions
India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions